US Cycle Control and Blood Pressure Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00920985
Recruitment Status : Completed
First Posted : June 16, 2009
Last Update Posted : October 9, 2015
Information provided by (Responsible Party):

Brief Summary:
Birth Control Patch Study

Condition or disease Intervention/treatment Phase
Contraception Drug: Gestodene/EE (FC Patch Low, BAY86-5016) Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 346 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Study Start Date : June 2009
Actual Primary Completion Date : August 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control

Arm Intervention/treatment
Experimental: Arm 1 Drug: Gestodene/EE (FC Patch Low, BAY86-5016)
21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2

Active Comparator: Arm 2 Drug: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1

Primary Outcome Measures :
  1. Cycle control parameters and bleeding pattern indices [ Time Frame: Treatment cycles 2-7 ]

Secondary Outcome Measures :
  1. Number of pregnancies while on treatment up to 14 days after removal of the last patch [ Time Frame: 7 treatment cycles each consisting of 28 days and follow-up period of 14 days ]
  2. Evaluation of blood pressure changes during the dosing-free interval [ Time Frame: 7 treatment cycles each consisting of 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female subject requesting contraception
  • Age: 18 - 45 years (inclusive); smokers must not be older than 35 years at the time of informed consent
  • Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous 6 months)
  • History of regular cyclic menstrual periods

Exclusion Criteria:

  • Pregnancy or lactation
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other contraceptive methods than study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00920985

  Hide Study Locations
United States, Arizona
Chandler, Arizona, United States, 85225-2909
Glendale, Arizona, United States, 85304
Phoenix, Arizona, United States, 85032
Tucson, Arizona, United States, 85712
United States, California
Anaheim, California, United States, 92801
San Diego, California, United States, 92121
United States, Florida
Clearwater, Florida, United States, 33759
Daytona Beach, Florida, United States, 32114
Lake Worth, Florida, United States, 33461
Leesburg, Florida, United States, 34748
Miami, Florida, United States, 33169
United States, Georgia
Atlanta, Georgia, United States, 30342
Decatur, Georgia, United States, 30034
United States, Louisiana
Metairie, Louisiana, United States, 70006
United States, Michigan
Kalamazoo, Michigan, United States, 49009
United States, Missouri
St. Louis, Missouri, United States, 63141
United States, Nevada
Las Vegas, Nevada, United States, 89104
United States, New Jersey
New Brunswick, New Jersey, United States, 08901
United States, North Carolina
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Cincinnati, Ohio, United States, 45246
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19114
Pittsburgh, Pennsylvania, United States, 15206
Wexford, Pennsylvania, United States, 15090
United States, South Carolina
Columbia, South Carolina, United States, 29201
United States, Virginia
Richmond, Virginia, United States, 23294
United States, Washington
Renton, Washington, United States, 98055
Seattle, Washington, United States, 98105
United States, Wisconsin
La Crosse, Wisconsin, United States, 54691
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bayer Identifier: NCT00920985     History of Changes
Other Study ID Numbers: 91556
First Posted: June 16, 2009    Key Record Dates
Last Update Posted: October 9, 2015
Last Verified: January 2014

Keywords provided by Bayer:
Pregnancy prevention
Female contraception

Additional relevant MeSH terms:
Contraceptive Agents
Contraceptives, Oral
Ethinyl Estradiol
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptives, Oral, Synthetic